Milewski M,Jakiela B,Zolcinski M,et al.[Mycophenolate mofetil maintenance therapy in lupus nephritis][J].Pol Arch Med Wewn,2006,116(4):947-954.
[2]
Laskari K,Tzioufas AG,Antoniou A,et al.Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis[J].J Rheumatol,2011,38(7):1 304-1 308.
[3]
Li X,Ren H,Zhang Q,et al.Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis[J].Nephrol Dial Transplant,2012,27(4):1 467-1 472.
[4]
Wang J,Hu W,Xie H,et al.Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy:mycophenolate mofetil or intravenous cyclophosphamide[J].Lupus,2007,16(9):707-712.
[5]
Urowitz MB,Ibanez D,Ali Y,et al.Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide[J].J Rheumatol,2007,34(7):1 491-1 496.
[6]
Cunha I,Saavedra MJ,Pereira DSJ,et al.[Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus][J].Acta Reumatol Port,2008,33(1):69-76.
[7]
Walsh M,James M,Jayne D,et al.Mycophenolate mofetil for induction therapy of lupus nephritis:a systematic review and meta-analysis[J].Clin J Am Soc Nephrol,2007,2(5):968-975.
[8]
Mak A,Cheak AA,Tan JY,et al.Mycophenolate mofetil is as efficacious as,but safer than,cyclophosphamide in the treatment of proliferative lupus nephritis:a meta-analysis and meta-regression[J].Rheumatology(Oxford),2009,48(8):944-952.
[9]
Appel GB,Contreras G,Dooley MA,et al.Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis[J].J Am Soc Nephrol,2009,20(5):1 103-1 112.
[10]
Chan TM,Tse KC,Tang CS,et al.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis[J].J Am Soc Nephrol,2005,16(4):1 076-1 084.
[11]
Ong LM,Hooi LS,Lim TO,et al.Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis[J].Nephrology(Carlton),2005,10(5):504-510.
[12]
Bradshaw SE.Lupus nephritis:Sustained proteinuria and dyslipidemia are risk factors for progressive CKD in patients with lupus nephritis[J].Nat Rev Nephrol,2011,7(4):184.
[13]
Houssiau FA,Ginzler EM.Current treatment of lupus nephritis[J].Lupus,2008,17(5):426-430.
[14]
Li EK,Tam LS,Zhu TY,et al.Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?[J].Rheumatology(Oxford),2009,48(8):892-898.
[15]
Ginzler EM,Dooley MA,Aranow C,et al.Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J].N Engl J Med,2005,353(21):2 219-2 228.
[16]
Onishi A,Sugiyama D,Tsuji G,et al.Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population:a retrospective study[J].Mod Rheumatol,2013,23(1):89-96.
